Following Majesco Entertainment, Inc.'s (NASDAQ: COOL) announcement on 12/8/16 that it had signed a definitive merger agreement with PolarityTE™, Inc. www.polarityte.com, Polarity has revealed the first wave of their World Class Clinical Advisory Board, as Drs. Michael Grant, Stephen Milner, and Anand Kumar. Chairman and CEO, Denver Lough MD, PhD elaborated, "Our goal is to build an entirely new type of regenerative medicine company with PolarityTE™. The PolarityTE™ Clinical Advisory Board will play a critical role in translating our regenerative technology into pragmatic clinical practice, helping us address the realities of the field on a real-time basis. It is this tangible feedback that allows PolarityTE™ technology to evolve quickly under the guidance of thought leaders in reconstructive surgery and regenerative medicine, while permitting our platform to break into new markets and develop new integrative technologies. We are extremely excited to announce the first tier of our world class clinical advisory board" as:
Michael P Grant MD, PhD, FACS
Paul N. Manson Distinguished Professor and Chief
Plastic, Reconstructive and Maxillofacial Surgery
R Adams Cowley Shock Trauma Center
University of Maryland Medical Center
Stephen Milner MD, DDS, DSc, FRCSE, FACS
Professor of Plastic and Reconstructive Surgery and Pediatrics at Johns Hopkins School of Medicine,
Director of the Johns Hopkins Burn Center,
Professor at the Bloomberg School of Public Health,
Director of the Michael D Hendrix Burn Research Center,
Adjunct Professor Uniformed Services University of the Health Sciences,
Honorary Civilian Consultant Advisor to the British Army in Plastic Surgery and Burns
Anand Kumar MD, FACS
Associate Professor of Plastic and Reconstructive Surgery
Director, Center for Pediatric Craniofacial Surgery
Johns Hopkins School of Medicine
About PolarityTE
PolarityTE, Inc. is the owner of a novel regenerative medicine and tissue engineering platform developed and patented by Denver Lough MD, PhD. This radical and proprietary technology employs a patients' own cells for the healing of full-thickness functionally-polarized tissues. If clinically successful, the PolarityTE platform will be able to provide medical professionals with a truly new paradigm in wound healing and reconstructive surgery by utilizing a patient's own tissue substrates for the regeneration of skin, bone, muscle, cartilage, fat, blood vessels and nerves. It is because PolarityTE uses a natural and biologically sound platform technology, which is readily adaptable to a wide spectrum of organ and tissue systems, that the company and its world-renowned clinical advisory board, are poised to drastically change the field and future of translational regenerative medicine. More info can be found online at www.polarityte.com Welcome to the Shift™
